2021
Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, Caballero D, Advani R, de Oña R, Niebla A, Terol M, Eva D, Bendris N, Ahsan J, Leoni M, Foss F. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 2021, 138: 621. DOI: 10.1182/blood-2021-147279.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaProgression-free survivalOverall response rateT-cell lymphomaOverall survivalPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaOpen-label trialPhase 2 studyNegative prognostic factorDuration of responsePotential predictive biomarkersNon-Hodgkin lymphomaT-cell homingProgression of diseasePTCL patientsRefractory PTCLUnacceptable toxicityAdult patientsPrognostic factorsPredictive biomarkersLugano classificationCXCL12 expressionReceptor CXCR4New therapies
2017
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma
Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 2017, 131: 888-898. PMID: 29233821, PMCID: PMC5824337, DOI: 10.1182/blood-2017-08-802470.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overClass I Phosphatidylinositol 3-KinasesClass Ib Phosphatidylinositol 3-KinaseFemaleHumansIsoquinolinesLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMaleMaximum Tolerated DoseMiddle AgedPhosphoinositide-3 Kinase InhibitorsPrognosisPurinesSafetySkin NeoplasmsTissue DistributionConceptsT-cell lymphomaPhospho-AktImmunosuppressive M2-like phenotypeCutaneous T-cell lymphomaNonmalignant immune cellsOpen-label studySerum cytokine profilesAcceptable safety profileImmune-mediated effectsPhase 1 trialOverall response rateM1-like phenotypePatient-derived xenograftsTumor-associated macrophagesM2-like phenotypeInflammatory M1-like phenotypeT cell growthRefractory PTCLTransaminase increaseAdverse eventsClinical responseCytokine profileMaculopapular rashComplete responsePreclinical evidence
2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker Research 2014, 2: 16. PMID: 25279222, PMCID: PMC4181623, DOI: 10.1186/2050-7771-2-16.Peer-Reviewed Original ResearchMajority of discontinuationsCommon adverse eventsRefractory PTCLAdverse eventsT-cell lymphomaHematologic toxicityAE profileRomidepsin treatmentGreater incidencePoor bone marrow reserveCutaneous T-cell lymphomaRefractory T-cell lymphomaBone marrow reserveDose of romidepsinFrequent hematologic toxicityLeast stable diseaseSimilar AE profilesTreatment cycles 1Severe hematologic toxicityDurable clinical responsesRefractory aggressive lymphomaOverall clinical benefitCycle 1Overall AE profileNovel drug therapies
2011
Relapsed and refractory PTCL—into the therapeutic abyss
Foss F. Relapsed and refractory PTCL—into the therapeutic abyss. Nature Reviews Clinical Oncology 2011, 8: 321-322. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.Peer-Reviewed Original Research